Advanced knowledge of neurodegenerative diseases achieved by Trophos Trophos SA.

Advanced knowledge of neurodegenerative diseases achieved by Trophos Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served requirements in neurology and cardiology, today the conclusion of the pan-European MitoTarget Project announces, the EU funded orphan disease task, with submission of the ultimate are accountable to the EC. The outcomes obtained in this task included additional confirmation that mitochondrial dysfunction performs an important role in neuron loss of life, and then the progression of neurodegenerative illnesses Click to read more . The MitoTarget task contributed towards broader research necessary to discover which dysfunction/s is the leading reason behind neurodegenerative diseases, key to locating effective drug targets later on.